A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Hunner Type Interstitial Cystitis
Status: Recruiting
Location: See all (18) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Hunner Type Interstitial Cystitis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Japanese (both sexes)
• Age (at the time of informed consent): 18 years and older
• Outpatient
• Patients who are considered capable of understanding the study procedures and completing the pain diary, bladder diary, and questionnaires appropriately by the investigator (sub-investigator）
• Patients given a diagnosis of HIC by cystoscopy
• Patients with chronic pelvic pain involving the bladder and lower urinary tract symptoms such as increased micturition and pollakiuria
Locations
Other Locations
Japan
Nakamura Hospital
RECRUITING
Beppu
University Of Yamanashi Hospital
RECRUITING
Chūō
Harasanshin Hospital
RECRUITING
Fukuoka
Japanese Red Cross Gifu Hospital
RECRUITING
Gifu
Kanto Rosai Hospital
RECRUITING
Kawasaki
Rakuwakai Marutamachi Hospital
NOT_YET_RECRUITING
Kyoto
Ueda Clinic
RECRUITING
Kyoto
Shinshu University Hospital
RECRUITING
Matsumoto
The Jikei University Hospital
RECRUITING
Minato-ku
Kyorin University Hospital
RECRUITING
Mitaka
Nagasaki University Hospital
RECRUITING
Nagasaki
Nagoya University Hospital
RECRUITING
Nagoya
Okayama University Hospital
RECRUITING
Okayama
Nanri Urological Clinic
RECRUITING
Saga
Izumi Chuo Hospital
RECRUITING
Sendai
Kurosawa Hospital Health Park Clinic
RECRUITING
Takasaki
The University Of Tokyo Hospital
RECRUITING
Tokyo
Toyama Rosai Hospital
RECRUITING
Uozu
Contact Information
Primary
North America Clinical Trial Support Desk
clinical_trial@ono-pharma.com
+18665877745(Toll-Free)
Backup
International Clinical Trial Support Desk
clinical_trial@ono-pharma.com
+17162141777(Standard)
Time Frame
Start Date: 2025-04-02
Estimated Completion Date: 2026-08
Participants
Target number of participants: 50
Treatments
Experimental: ONO-1110
ONO-1110 tablets once a day
Placebo_comparator: Placebo
Placebo tablets once daily
Related Therapeutic Areas
Sponsors
Leads: Ono Pharmaceutical Co. Ltd